ループス治療薬市場- 世界の産業規模、シェア、動向、機会、予測：治療タイプ別、投与経路別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

ループス治療薬の世界市場は、2024年には71億2,000万米ドルと評価され、2030年には107億4,000万米ドルに達し、CAGR 7.09％で成長すると予測されています。

この成長は、身体の免疫系が自身の組織や臓器を攻撃する自己免疫疾患であるループスの世界の有病率の増加に大きく起因しています。この病気は炎症を引き起こし、関節、皮膚、腎臓、肺、心臓、脳など複数の器官に影響を及ぼします。狼瘡は多様で他の疾患と症状が重複するため、診断が難しいことが多いです。多くの場合、特徴的な症状として、頬全体に蝶形の発疹が現れます。遺伝的な素因を持つ人もいるが、感染症や薬物、日光への暴露が引き金になることもあります。米国狼瘡財団によると、世界中で500万人以上が狼瘡に罹患しており、その主な年齢は15歳から44歳です。

市場促進要因

全身性エリテマトーデス（SLE）の世界の有病率の上昇

主な市場課題

先進治療薬の高コストと低所得地域でのアクセス制限

主要市場動向

ループス治療における個別化医療の採用拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 COVID-19が世界のループス治療薬市場に与える影響

第6章 臨床試験分析

第7章 世界のループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療タイプ別（NSAIDs、コルチコステロイド、抗マラリア薬、免疫抑制剤、生物学的製剤、その他）
  • 投与経路（経口、静脈内、皮下）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 地域別

第8章 北米のループス治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第9章 欧州のループス治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア

第10章 アジア太平洋地域のループス治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第11章 南米のループス治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第12章 中東・アフリカのループス治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第13章 市場力学

• 促進要因
• 課題

第14章 市場動向と発展

• 製品上市
• 合併と買収
• 最近の動向

第15章 世界のループス治療薬市場：SWOT分析

第16章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第17章 競合情勢

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

第18章 戦略的提言

第19章 調査会社について・免責事項

The Global Lupus Therapeutics Market was valued at USD 7.12 billion in 2024 and is projected to reach USD 10.74 billion by 2030, growing at a CAGR of 7.09%. This growth is largely attributed to the increasing global prevalence of lupus, an autoimmune condition in which the body's immune system attacks its own tissues and organs. The disease causes inflammation that can affect multiple systems, including the joints, skin, kidneys, lungs, heart, and brain. Diagnosing lupus is often difficult due to its diverse and overlapping symptoms with other conditions. A signature symptom in many cases is a butterfly-shaped rash across the cheeks. While some individuals are genetically predisposed, lupus can also be triggered by infections, medications, or exposure to sunlight. According to the Lupus Foundation of America, over five million people worldwide are affected by lupus, primarily those aged 15 to 44.

Key Market Drivers

Rising Global Prevalence of Systemic Lupus Erythematosus (SLE)

The growing prevalence of systemic lupus erythematosus (SLE), the most common and severe form of lupus, is a significant driver of the lupus therapeutics market. SLE is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues, resulting in inflammation and organ damage. This condition is especially prevalent among women of reproductive age and is disproportionately seen in African American, Hispanic, and Asian populations. The increasing awareness, improved diagnostic capabilities, and rising incidence of autoimmune disorders globally are collectively contributing to the market's expansion.

Key Market Challenges

High Cost of Advanced Therapies and Limited Access in Low-Income Regions

Despite advancements in treatment, the high cost of biologics and targeted lupus therapies presents a major challenge, particularly in low- and middle-income regions. These innovative drugs, although effective, are often unaffordable for many patients-even in high-income countries with insurance coverage. In regions with limited healthcare infrastructure and funding, access to these treatments remains restricted. The economic burden limits the use of advanced therapeutics, thereby widening the treatment gap. Additionally, constrained healthcare budgets and inadequate reimbursement policies further hinder the adoption of these high-cost medications.

Key Market Trends

Growing Adoption of Personalized Medicine in Lupus Treatment

An emerging trend in the lupus therapeutics market is the growing shift toward personalized medicine. This approach tailors treatment to an individual's genetic, molecular, and phenotypic characteristics. Personalized strategies are especially important in lupus, which is marked by variable symptoms, disease progression, and treatment responses.

Advances in genomics, proteomics, and immunophenotyping are enabling more precise patient stratification and treatment planning. For instance, researchers funded by the NIH have identified immune pathway signatures-such as type I interferon activity-that may help predict patient response to specific biologics. Clinical trials are now being designed with biomarker-driven enrollment to increase efficacy, reduce side effects, and streamline drug approvals.

These innovations are supported by government initiatives such as the FDA's Precision Medicine Initiative and the European Union's Horizon Europe framework, both of which prioritize the development of targeted therapies for complex diseases like lupus.

Key Market Players

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Lupus Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

• NSAIDs
• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics
• Others

Lupus Therapeutics Market, By Route of Administration:

• Oral
• Intravenous
• Subcutaneous

Lupus Therapeutics Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lupus Therapeutics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lupus Therapeutics Market.

Available Customizations:

Global Lupus Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
  • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
  • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 7.2.4. By Region
  • 7.2.5. By Company (2024)
• 7.3. Market Map
  • 7.3.1. By Treatment Type
  • 7.3.2. By Route of Administration
  • 7.3.3. By End User
  • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Lupus Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. Canada Lupus Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Mexico Lupus Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Lupus Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. France Lupus Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End User
  • 9.3.4. Spain Lupus Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment Type
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By End User
  • 9.3.5. Italy Lupus Therapeutics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Treatment Type
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Lupus Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. India Lupus Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Japan Lupus Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End User
  • 10.3.4. South Korea Lupus Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment Type
      • 10.3.4.2.2. By Route of Administration
      • 10.3.4.2.3. By End User
  • 10.3.5. Australia Lupus Therapeutics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Treatment Type
      • 10.3.5.2.2. By Route of Administration
      • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Treatment Type
  • 11.2.2. By Route of Administration
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Lupus Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Treatment Type
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By End User
  • 11.3.2. Argentina Lupus Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Treatment Type
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By End User
  • 11.3.3. Colombia Lupus Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Treatment Type
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Treatment Type
  • 12.2.2. By Route of Administration
  • 12.2.3. By End User
  • 12.2.4. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Lupus Therapeutics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Treatment Type
      • 12.3.1.2.2. By Route of Administration
      • 12.3.1.2.3. By End User
  • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Treatment Type
      • 12.3.2.2.2. By Route of Administration
      • 12.3.2.2.3. By End User
  • 12.3.3. UAE Lupus Therapeutics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Treatment Type
      • 12.3.3.2.2. By Route of Administration
      • 12.3.3.2.3. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. GSK plc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Novartis AG
• 17.3. AstraZeneca
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. Eli Lilly and Company
• 17.6. ImmuPharma PLC
• 17.7. Pfizer Inc.
• 17.8. Sanofi S.A.
• 17.9. Bristol-Myers Squibb Company
• 17.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer